Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "2-methoxyestradiol" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-3 z 3
    Tytuł:
    Dual effect of 2-methoxyestradiol on cell cycle events in human osteosarcoma 143B cells.
    Autorzy:
    Gołębiewska, Justyna
    Rozwadowski, Piotr
    Spodnik, Jan
    Knap, Narcyz
    Wakabayashi, Takashi
    Woźniak, Michał
    Powiązania:
    https://bibliotekanauki.pl/articles/1043807.pdf
    Data publikacji:
    2002
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    osteosarcoma 143B cells
    2-methoxyestradiol
    apoptosis
    cell cycle
    Opis:
    We have demonstrated for the first time that the steroid metabolite, 2-methoxyestradiol (2-ME) is a powerful growth inhibitor of human osteosarcoma 143 B cell line by pleiotropic mechanisms involving cell cycle arrest at two different points and apoptosis. The ability of 2-ME to inhibit cell cycle at the respective points has been found concentration dependent. 1 μM 2-ME inhibited cell cycle at G1 phase while 10 μM 2-ME caused G2/M cell cycle arrest. As a natural estrogen metabolite 2-ME is expected to perturb the stability of microtubules (MT) in vivo analogously to Taxol - the MT binding anticancer agent. Contrary to 2-ME, Taxol induced accumulation of osteosarcoma cells in G2/M phase of cell cycle only. The presented data strongly suggest two different mechanisms of cytotoxic action of 2-ME at the level of a single cell.
    Źródło:
    Acta Biochimica Polonica; 2002, 49, 1; 59-65
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Nowotwory kości : nowe możliwości terapeutyczne
    Bone cancer : new therapeutic possibility
    Autorzy:
    Wyszkowska, Roksana
    Drzeżdżon, Joanna
    Musiał, Claudia
    Górska-Ponikowska, Magdalena
    Powiązania:
    https://bibliotekanauki.pl/articles/171964.pdf
    Data publikacji:
    2019
    Wydawca:
    Polskie Towarzystwo Chemiczne
    Tematy:
    kostniakomięsak
    chrzęstniakomięsak
    włókniakomięsak
    tlenek azotu
    2-metoksyestradiol
    osteosarcoma
    chondrosarcoma
    fibrosarcoma
    nitric oxide
    2-methoxyestradiol
    Opis:
    Among bone tumours, Osteosarcoma (OS), Chondrosarcoma (CS) and Fibrosarcoma (FS) are highly metastatic with poor prognostic for survival. Standard procedures as surgery resection, radiotherapy and chemotherapy do not lead to full recovery or they do not affect metastasis [1-4]. Nowadays new molecular targets to cure cancer are during clinical trials. Clinical trials for OS are focused on using monoclonal antibody (dinutuximab) [5], immunotherapy (as using GM-CSF with influence on white blood cells) [6] or compounds acting as VEGFR inhibitor or PDGFR inhibitor - to reduce metastasis [7-9]. Clinical trials for CS are targeting the hedgehog pathway, focused on its inhibition [10], inhibition of IDH1/2 (common mutation in CS leading to hypermethylation) [11] or, as in OS treatment, inhibition of metastasis by acting on VEGFR [12]. Beyond new chemotherapy and chemotherapy correlated with radiotherapy [13] clinical trials for FS are targeting gene fusion NTRK acting through inhibition of tropomyosin kinase receptor [14]. This approach to treatment is a novelty on the global scale [15]. Nitric oxide (NO) has many biological functions, e.g.: acting as neurotransmitter, reduced aggregation of platelets, acting as EDRF or reducing the oxidative stress in tumours [16-18]. Due to the dual nature of NO [19] anti-proliferative, pro-apoptotic and cell cycle arrest effect of NO were observed [20-25]. It could be a new area to find novel anti-cancer compound. One of the molecular targets under the scientists consideration is the activation of nitric oxide synthase (NOS). Górska-Ponikowska et al. [26-28] focused on experiments on OS 143B cells with 2-methoxyestradiol (2-ME) treatment, potentially novel compound playing the role of n-NOS activator. The researchers reported influence of 2-ME on down-regulation of mitochondrial biogenesis via direct influence on n-NOS level in OS 143B cells. What is more, L-lactate was indicated as potential molecular marker of anticancer therapy of tumours with metastasis.
    Źródło:
    Wiadomości Chemiczne; 2019, 73, 11-12; 701-713
    0043-5104
    2300-0295
    Pojawia się w:
    Wiadomości Chemiczne
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Biologia i chemia nowotworu płuca
    Biology and chemistry of lung cancer
    Autorzy:
    Musiał, Claudia
    Zaucha, Renata
    Kuban-Jankowska, Alicja
    Kamm, Anna
    Górska-Ponikowska, Magdalena
    Powiązania:
    https://bibliotekanauki.pl/articles/972293.pdf
    Data publikacji:
    2019
    Wydawca:
    Polskie Towarzystwo Chemiczne
    Tematy:
    farmakoprewencja raka płuca
    biologia raka płuca
    chemia raka płuca
    indukcja hormonalna
    2-metoksyestradiol
    lung cancer pharmacoprevention
    biology of lung cancer
    chemistry of lung cancer
    hormonal induction
    2-methoxyestradiol
    Opis:
    Lung cancer is the most common fatal cancer disease in the world. A characteristic feature of lung cancer is genetic diversity. In the overwhelming majority of cases, smoking is the most important etiopathogenic factor. Lung cancer is a cancer with a very bad prognosis regarding long-term survival. The risk of lung cancer depends primarily on active or passive exposure to the carcinogenic components of tobacco smoke. According to available data, the development of lung cancer in addition to active and passive smoking is directly affected by environmental pollution such as smog and fumes, ionizing radiation, mycotoxins and long-term exposure to asbestos (occupational exposure). Research on the pharmacoprevention of lung cancer began over 30 years ago. The first nutrient that the researchers said could inhibit the development of lung cancer was beta carotene. Unfortunately, long-term regular supplementation with high doses of antioxidant in the form of beta-carotene brought the opposite effect. An increase in the incidence of lung cancer was found in people who received beta carotene in the form of a synthetic food supplement. The other component tested was N-acetylcysteine. It is a sulfur compound and a powerful antioxidant that supports the synthesis of glutathione and cysteine, with destructive effects on carcinogenic substances. N-acetyl-cysteine, used in the form of NAC adduct and epigallocatechin-3-gallate, showed efficacy in inhibiting the development of lung cancer only in animal models. In the pharmacoprevention of lung cancer, the use of vitamin E was also tested in the form of tocotrienol and tocopherol. The following work also shows the existence of a high concentration correlation which belongs to the steroid hormone, mainly estrogen, in the blood and the development of lung cancer in women. An increased risk of lung cancer has been observed in women undergoing long-term hormone replacement therapy. The results show that 2-methoxyestradiol, the endogenous metabolite of 17ß-estradiol, shows positive results that inhibit the growth of lung cancer cell lines. The aim of the work was to present the correlation between tobacco abuse and passive smoking and lung cancer, pharmacoprevention of lung cancer and the association of elevated estrogen concentration in women with an increased risk of lung cancer.
    Źródło:
    Wiadomości Chemiczne; 2019, 73, 7-8; 505-522
    0043-5104
    2300-0295
    Pojawia się w:
    Wiadomości Chemiczne
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-3 z 3

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies